Background: Our primary goal is to describe the prevalence, severity, and risk of cognitive impairment (CI) by estimated glomerular filtration rate (eGFR, in mL/min/1.73 m 2 ) in a cohort enriched for advanced chronic kidney disease (CKD; eGFR < 45), adjusting for albuminuria, as measured by urine albumin-to-creatinine ratio (UACR, in mg/g). As both eGFR and albuminuria are associated with CI risk in CKD, we also seek to determine the extent that eGFR remains a useful biomarker for risk of CI in those with CKD and concomitant albuminuria. Methods: Chi-square tests measured the prevalence of severe CI and mild cognitive impairment (MCI) by eGFR level. Logistic regression models and generalized linear models measured risk of CI by eGFR, adjusted for UACR. Results: Participants were 574 adults with a mean age of 69; 433 with CKD (eGFR < 60, nondialysis) and 141 controls (eGFR ≥ 60). Forty-eight percent of participants with CKD had severe CI or MCI. The prevalence of severe CI was highest (25%) in those with eGFR < 30. eGFR < 30 was only associated with severe CI in those without albuminuria (UACR < 30; OR = 3.3; p = .02) and was not associated with MCI in similar models. Conclusions: One quarter of those with eGFR < 30 had severe CI. eGFR < 30 was associated with over threefold increased odds of severe CI in those with UACR < 30, but not with UACR > 30, suggesting that eGFR < 30 is a valid biomarker for increased risk of severe CI in those without concomitant albuminuria.
Chronic kidney disease (CKD) has been proposed as a model of accelerated brain aging based on the high number of individual and aggregate risk factors for cognitive impairment (CI) that are related to both renal and vascular comorbidities (1, 2) . There is a cross-sectional relation between estimated glomerular filtration rate (eGFR, in mL/min/1.73 m 2 ) and cognitive function (3) (4) (5) (6) and an association between reduced or decreasing eGFR and incident CI or dementia (7) (8) (9) . Albuminuria, a systemic marker of endothelial dysfunction and microvascular disease (10, 11) , is also strongly associated with CI (12, 13) , but is less commonly measured than eGFR in older adults in routine clinical care (12) .
In our recent cross-sectional analyses from the prospective, longitudinal, BRain IN Kidney disease (BRINK) study, those with an eGFR < 30 performed significantly worse on individual measures of cognitive function compared to those with an eGFR ≥ 30. However, findings were not adjusted for albuminuria (3) . Our primary goal is to describe the prevalence, severity, and risk of CI by eGFR level, adjusting for albuminuria, as measured by urine albumin-to-creatinine ratio (UACR, in mg/g). Given evidence that albuminuria is also associated with CI risk in CKD (12, 13) , we additionally seek to determine whether eGFR remains a useful biomarker for risk of CI in CKD with concomitant albuminuria. Lastly, we will characterize cognitive domain performance by CKD severity level to determine the extent that memory, executive function and language performance are impacted in advanced CKD (3, 14, 15) .
Methods

Participants
Study design, sample size calculations, and recruitment strategy for the BRINK study are described in detail elsewhere (3) . In order to enrich our cohort with advanced CKD, participants were recruited from four community nephrology and diabetes clinics in the Minneapolis/St. Paul area. Eligibility criteria were as follows: 45 years or older, able to complete a 90-minute cognitive and physical function battery, and English as a first language. Exclusion criteria included recent psychosis, current chemical dependency, long-term high-dose narcotic use, nursing home residence, dialysis dependency, or kidney transplant recipient at the time of screening. Participants were excluded at screening if they were unable to complete the Modified Mini-Mental State Examination (3MS) (16) .
Definitions of categories related to indicators of CKD were based on Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines for eGFR only (17) . Control participants were defined as having eGFR ≥ 60, although this group did include some with early CKD (ie, those with eGFRs of 60-90, with or without albuminuria). Control participants were recruited to approximate the mean age and similar racial and gender distribution of the combined CKD groups. We recruited a high proportion of participants with diabetes in our CKD cohort to reflect the approximate 50% prevalence of diabetes in the general CKD population (18) . The CKD groups were defined as mild CKD (eGFR 45 to <60), moderate CKD (eGFR 30 to <45), and severe nondialysis CKD (eGFR < 30). UACR was defined as normal (UACR < 30), moderately increased (UACR 30-300) and severely increased (UACR > 300), with acknowledgment that KDIGO guidelines group normal and mildly increased albuminuria under one category (ie, UACR < 30). For this set of analyses, we use the term cohort to describe the entire BRINK sample and the term prevalence to describe the frequency of CI in the cohort.
The institutional review boards of collaborating institutions approved the study (Hennepin County Medical Center approval no: 11-3393; University of Minnesota: 1203M11122; Veterans Affairs Medical Center: 4364-B; and HealthPartners Institute: A12-282).
Laboratory and Other Measures
Nonfasting blood samples were drawn from an antecubital vein and urine samples were obtained at the baseline visit. Baseline eGFR was calculated from the serum creatinine using the CKD Epidemiology Collaboration creatinine equation (19) . Albuminuria was measured with a spot urine sample UACR. (24) (25) (26) and Category Fluency (Animals) (27) ; and the Digit Span Total (DS) subtest of the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) (28) . Performance was measured using raw and T-scores for the following individual tests: HVLT-R, BVMT-R, CTT-1, CTT-2, SDMT, and Letter and Category Fluency. Administration and norming procedures were followed per published guidelines (20) (21) (22) (23) (24) (25) (26) (27) (28) , with the exception of the administration of Category Fluency (Animals), which was based on extending the animal naming portion of the 3MS (16) to 60 seconds. A T-score of 50 denotes normal cognition; 1 SD = 10. T-scores were based on published norms that adjust for age and sometimes education (CTT-1, CTT-2, SDMT) and race (Letter and Category Fluency). For the DS and Letter Fluency, age-adjusted scaled scores (with mean of 10 and standard deviation [SD] of 3) were converted to T-scores.
Measurement of Baseline Cognitive Function
Identification of Cognitive Domains
Factor analysis methods were used to identify cognitive domains that best classified results from the individual cognitive tests. A three-factor model was adequately supported with the use of seven cognitive measures (Digit Span Total was eliminated): memory (HVLT-R and BVMT-R), executive function/processing speed (SDMT, CTT-1, CTT-2), and language (Letter and Category Fluency). For the purpose of our analyses, we will use the term "executive function" to describe the executive function/processing speed domain.
Classifying Severity of CI and Performance by Cognitive Domain
To determine CI severity, the mean of each cognitive domain was calculated and then Diagnostic and Statistical Manual of Mental Disorders, 5 th edition (DSM-5) (29) cognitive performance guidelines were applied to determine whether performance in one or more domains fell within the range of Major Neurocognitive Disorder ("dementia") or Mild Neurocognitive disorder ("MCI"). However, the DSM-5 full criteria for dementia require verification of functional decline, and study partner report of functional status was not consistently available in our cohort. Consequently, we use the term "severe cognitive impairment (severe CI)" to describe the group with performance within the dementia range as set forth by the DSM-5 ( Table 1) . 
Statistical Analyses
Baseline mean differences in continuous demographic characteristics between eGFR groups were evaluated with analysis of variance or the Kruskal-Wallis test (for skewed variables). Chi-square tests were used to evaluate differences in baseline categorical demographic characteristics by eGFR group and unadjusted associations between CI (normal, MCI or severe CI) and eGFR group (control, mild, moderate, and severe CKD).
Logistic regression models were used to estimate adjusted associations between eGFR group and severity of CI (MCI and severe CI). Generalized linear models were used to test for differences in adjusted mean domain scores (LS means) between eGFR groups. All CI severity models and models for domain performance were adjusted for age, gender, race (African American or non-African American), years of education, albuminuria (UACR), medical history of TIA/stroke, diabetes, and hypertension. As eGFR and UACR are strongly correlated, we also tested for an a priori interaction between eGFR and UACR in each model. The association between eGFR or UACR and CI may be stronger among older adults (30) . Subsequently, we tested for a possible interaction between age and UACR and between age and eGFR in adjusted logistic regression models for severe CI and MCI and in generalized linear models for cognitive domains. Alpha level was 0.05 for significant associations and 0.10 for significant interaction terms. SAS version 9.4 was used for all statistical analyses.
Results
Baseline Characteristics
The cohort of 574 BRINK participants included 92 (16.0%) with mild CKD (eGFR 45 to <60), 193 (33.6%) with moderate CKD (eGFR 30 to <45), 148 (25.8%) with severe CKD (eGFR < 30), and 141(24.6%) controls (eGFR ≥ 60). Mean age was 69.2 ± 9.8 years, half were male, mean education level was 14.3 ± 2.8 years, and 20.7% classified their race as African American or other. Mean eGFR for the control group was 81.8 ± 14.8, compared with 34.3 ± 11.8 in participants with reduced eGFR. Median UACR for the control group was 3.1, compared to 52.6 for participants with reduced eGFR. The CKD groups had higher rates of diabetes and hypertension and higher mean systolic blood pressure compared with controls. There were no significant differences between eGFR groups in race distribution, history of prior TIA/stroke, diastolic blood pressure, or apolipoprotein E (APOE) ε4 allele frequency (Table 2) .
Baseline Prevalence of CI
At baseline 48% of those with CKD (eGFR < 60) and 41% of controls (eGFR ≥ 60) were characterized as severe CI or MCI. The highest prevalence of severe CI was in those with severe kidney disease (eGFR < 30) at 25.0%, compared with 15.6% in the control group. Prevalence of MCI was highest (31.8%) in those with mild kidney disease (eGFR 45 to <60). Unadjusted chi square analysis revealed that eGFR was significantly associated with CI level (p = .03; Table 3 ). Additional unadjusted chi-square analyses investigated the association between MCI or severe CI and eGFR using three different eGFR cutpoints: <30 vs ≥30, <45 vs ≥45, and <60 vs ≥60. The only significant association was between eGFR with cutpoint at 30 and severe CI (25.0% for eGFR < 30 vs 13.9% for eGFR ≥ 30, p = .002). There were no significant associations between eGFR cutpoints and MCI.
In a logistic regression model for severe CI adjusted for age, education, gender, race, albuminuria, TIA/stroke, diabetes, and hypertension, there was a significant interaction between eGFR (<30 vs ≥30) and UACR (p = .05). Stratified models to examine this interaction revealed that eGFR (<30 vs ≥30) was significantly associated with severe CI in those with UACR <30 (OR = 3.3, 95% CI = 1.27, 8.50, p = .02); this association was no longer significant among those with a UACR 30-300 or UACR > 300 (Table 4 ). There were no significant differences in the prevalence of severe CI between UACR categories (p = .13; Table 4 ).
Secondary Analyses Related to African American Race and Age
The relation between eGFR group and CI level was not consistently linear (Table 3) . For example, while the highest prevalence of severe CI was in the eGFR < 30 group (25.0%), the prevalence of severe CI was higher in the eGFR control group (15.6%) than the eGFR 45 to <60 (12%) and 30 to <45 groups (13.5%). We also noted a nonlinear trend in the distribution of African American race across groups ( All models for severe CI and MCI were adjusted for AA race, diabetes, stroke/TIA, age, and education to account for these multiple and potentially confounded contributors to CI in the BRINK cohort. Lastly, in fully-adjusted logistic regression models, we found no significant interaction between age group and eGFR (p = .33) or UACR (p = .60) on severe CI.
Baseline Cognitive Domain Scores
Performance in each cognitive domain varied by eGFR group (<30 vs ≥30), as measured by least squares (LS) mean T scores adjusted for age, education, gender, race, albuminuria (UACR), TIA/stroke, diabetes, hypertension and, if present, the interaction between eGFR and UACR, age and eGFR, or age and UACR. In adjusted regression models, there was an interaction noted between eGFR and UACR on both memory (p = .03) and executive function performance (p = .005). Stratified models demonstrated that eGFR < 30 was significantly associated with lower performance in memory (p = .02) and executive function (p = .004) in those with normal UACR (<30) and those with UACR 30-300 (p = .02 for memory; p = .02 for executive function), but eGFR was not associated with lower memory (p = .54) or executive function performance (p = .21) in those with UACR > 300 (Table 5 ). In the adjusted regression model for language, eGFR < 30 was associated with reduced performance Note: CI = Cognitive impairment; eGFR = Estimated glomerular filtration rate; OR = Odds ratio; UACR = Urine albumin-to-creatinine ratio. The chi-square test for prevalence of CI by UACR group was not significant (p = .13). (p = .04); there was no significant interaction between eGFR and UACR (p = .17). There was a significant interaction between age and UACR on language performance (p = .02). In those aged 70 years or older, there was a lower LS mean language domain score for those with UACR 30-300 compared to UACR < 30 but these findings were only marginally significant (p = .05) There was no significant association between eGFR <45 vs ≥45 and memory (p = .28), executive function (p = .35), or language performance (p = .57) or between eGFR <60 vs ≥ 60 and memory (p =.74), executive function (p = .39), or language performance (p = 0.32).
Discussion
In this community-based clinic cohort enriched for advanced CKD, we found that 48% of those with CKD (eGFR < 60) had some level of CI at study baseline. Furthermore, one-quarter of those with severe CKD (eGFR < 30) demonstrated severe CI. For those without albuminuria (UACR < 30), the odds of severe CI were over three times higher for eGFR < 30 compared with eGFR ≥ 30. However, as UACR increased, eGFR < 30 was no longer associated with the odds of severe CI. Overall, these findings suggest that eGFR < 30 is a useful biomarker for increased risk of severe CI in those without concomitant albuminuria.
We are not aware of previous studies that have measured the burden or risk of CI by eGFR level within an enriched CKD cohort with a comprehensive battery of neuropsychological measures, while adjusting for concomitant albuminuria. A recent cross-sectional analysis of a large community sample in the Netherlands (the Maastricht Study) revealed that both eGFR and albuminuria were individually associated with cognitive function but this relation was limited to older adults (30) . However, the Maastricht study was not enriched for advanced CKD and included less than 4% with an eGFR < 60 (33), compared with 75% of participants in the BRINK cohort.
We anticipate that quantifying the prevalence of severe CI in CKD by eGFR level will increase the awareness of this burden among clinicians. Our results extend our previous work with individual cognitive measures (3) by clarifying that eGFR < 30 is associated with risk for severe CI in those without moderate to severely increased albuminuria (UACR ≥ 30). Our findings complement previous findings from the Reasons for Geographic and Racial Disparities in Stroke (REGARDS) study which utilized a brief screening measure to identify CI (34) . REGARDS results demonstrated that when stratified by UACR, reduced eGFR defined as eGFR < 60 was associated with higher odds for CI (OR =1.30), but solely at lower UACR levels (defined as UACR < 10) compared to other increased UACR groups. Our results also support their conclusion that albuminuria and low eGFR are complementary, but not additive risk factors for CI.
The lack of association between eGFR and CI in patients with moderate to severe albuminuria may be due to a number of factors. Albuminuria is associated with vascular endothelial function, which in the cerebral vasculature may result in breakdown of the blood brain barrier; this may result in cognitive changes associated with cerebrovascular and white matter changes seen on brain MRI in CKD (10) . It may be that UACR is more strongly associated with these neuropathological factors than eGFR, whereas an elevated eGFR may be more closely tied to neuronal toxins seen in uremia (35) . However, it remains the case that eGFR is often measured in routine clinical care, whereas albuminuria is not, except in those with diabetes or severe hypertension (12) .
In terms of cognitive domain performance, eGFR < 30 was associated with lower performance in the cognitive domains of memory and executive function in those without severely increased UACR (>300); eGFR < 30 was associated with reduced performance in language, independent of UACR levels. These findings support previous work that advanced CKD is associated with reduction in memory, executive function, and language performance (3, 14, 15) . However, we did not find an association between reduced eGFR and MCI. There are a limited number of studies in the CKD literature addressing MCI risk in CKD. It has been suggested that MCI may be more closely associated with an Alzheimer's disease/neurodegenerative process compared to the vascular processes that are hypothesized to contribute to CI in CKD (36) . The Einstein Aging Study, demonstrated that low eGFR (<45), compared to high eGFR (≥60) was associated with both amnestic and nonamnestic MCI subtypes in adjusted analyses (14) . Our results may differ from these findings due to our use of more liberal DSM-5 clinical criteria to define MCI (ie, impairment defined as 1-2 SD range below appropriate norms) versus the Petersen research criteria of 1.5 to 2 SD below appropriate norms (37) . Lastly, the sample size for our MCI models was reduced to only include those with MCI or normal cognitive function, thereby potentially limiting power to detect a significant association between eGFR and MCI.
We sought to recruit controls that approximated the distributions of key demographic variables in our CKD group, resulting in a similar percentage of African Americans in our control and CKD group. African Americans also had significantly higher rates of diabetes and TIA/stroke, and fewer years of education. Taken together, these factors likely contributed to the higher than expected rates of severe CI among controls in the BRINK cohort. Findings from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) MIND study demonstrated that baseline or persisting albuminuria (corrected for eGFR) were not associated with MRI measures associated with cognitive decline (38) . However, in related analyses of African American ACCORD MIND and African AmericanDiabetes Heart Study MIND (AA-DHS MIND) participants, even mild kidney dysfunction was associated with reduced performance in screening measures for CI, processing speed, executive function (39), as well as reduced grey matter volume and higher white matter lesion volume (40) . These findings underscore the importance of pursuing further investigation of the complex relationships between the multiple factors associated with CI in CKD populations, especially among underrepresented groups (39, 40) .
Strengths of our study include utilizing the DSM-5 cognitive criteria to define severe CI and MCI in a well-characterized cohort enriched with advanced CKD patients and measuring performance by cognitive domain based on clinically relevant neuropsychological measures. By characterizing the overall burden and severity of CI, we found that 48% of CKD participants had some level of CI at study baseline, further raising the awareness of the burden of CI in CKD. In addition, we measured the effect of eGFR adjusted for albuminuria in our analyses of risk for CI, thereby providing specific guidance for clinicians as regarding risk of CI in advanced CKD patients without albuminuria.
Several study limitations deserve mention. As this was a crosssectional analysis, causal inferences cannot be made regarding eGFR, albuminuria, and CI. The original study was not designed to subtype dementia (ie, vascular dementia vs Alzheimer's disease); therefore, we are unable to hypothesize the etiology of severe CI this cohort. We used the DSM-5 cognitive criteria for MCI and severe CI, but did not have comprehensive informant based functional status information to meet the full criteria for dementia. However, we believe that classification of severe CI is sufficient to inform providers and families with guidance in the clinical management of CKD patients.
Our findings may improve CKD patient care by identifying those at highest risk for severe CI and improving awareness of its relatively high prevalence in advanced CKD. Our results suggest that cognitive screening or referral for more detailed neuropsychological assessment is warranted for patients with eGFR < 30, especially if albuminuria is not suspected. Future BRINK analyses will characterize the trajectory and characteristics of cognitive decline to enable potential identification of mechanisms and modifiable risk factors for CI in this unique and complex population.
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